News Roche’s Alecensa approved in Europe, with head-to-head data ... Alecensa part of Roche's goal of becoming dominant player in NSCLC
News With all eyes on IO, Tagrisso could be AZ's ace card AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of blockbuster Crestor took its toll.
News Can Keytruda beat Opdivo to full UK access in lung cancer? A decisive moment in lung cancer treatment is nearing
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
